Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Israel
RecruitingPHASE2

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Parkinson Disease

Locations
  • Cedars-Sinai Department of Neurology, Los Angeles, California, United States
  • University of California San Francisco, San Francisco, California, United States
  • Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center, New York, New York, United States
  • Evergreen Health Laboratory, Kirkland, Washington, United States
  • Inland Northwest Research, Spokane, Washington, United States
  • Technische Universität Dresden, Dresden, Germany
  • University of Lübeck, Lübeck, Germany
  • University Hospital Tübingen, Tübingen, Germany
  • Rabin Medical Center, Petah Tikva, Israel
  • Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel
  • Tel Aviv Medical Center, Tel Aviv, Israel
  • Hospital Clinic de Barcelona, Barcelona, Spain
  • Hospital Universitari General de Catalunya, Barcelona, Spain
  • Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • Hospital Universitario Donostia, Donostia / San Sebastian, Spain
  • Universitary Hospital La Princesa, Madrid, Spain
  • IDIVAL/University Hospital Marques de Valdecilla, Santander, Spain
  • Hospital Universitario Virgen del Rocio, Seville, Spain